Gilead Sciences, Inc. (NASDAQ:GILD) Stock Holdings Increased by Avior Wealth Management LLC

Avior Wealth Management LLC lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 33.2% in the fourth quarter, Holdings Channel.com reports. The firm owned 12,551 shares of the biopharmaceutical company’s stock after acquiring an additional 3,129 shares during the quarter. Avior Wealth Management LLC’s holdings in Gilead Sciences were worth $1,140,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Beacon Investment Advisory Services Inc. lifted its position in shares of Gilead Sciences by 4.7% in the fourth quarter. Beacon Investment Advisory Services Inc. now owns 80,232 shares of the biopharmaceutical company’s stock worth $7,411,000 after purchasing an additional 3,637 shares in the last quarter. Bartlett & CO. Wealth Management LLC lifted its position in shares of Gilead Sciences by 149.1% in the fourth quarter. Bartlett & CO. Wealth Management LLC now owns 8,697 shares of the biopharmaceutical company’s stock worth $803,000 after purchasing an additional 5,205 shares in the last quarter. Albion Financial Group UT lifted its position in shares of Gilead Sciences by 182.7% in the fourth quarter. Albion Financial Group UT now owns 783 shares of the biopharmaceutical company’s stock worth $72,000 after purchasing an additional 506 shares in the last quarter. Advisory Alpha LLC acquired a new position in Gilead Sciences in the fourth quarter worth approximately $260,000. Finally, XML Financial LLC acquired a new position in Gilead Sciences in the fourth quarter worth approximately $203,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of research reports. Piper Sandler increased their price objective on Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Barclays increased their price objective on Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a report on Thursday, November 7th. The Goldman Sachs Group increased their price objective on Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a report on Thursday, November 7th. Maxim Group downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Finally, Bank of America restated a “buy” rating and issued a $109.00 price objective on shares of Gilead Sciences in a report on Tuesday, December 10th. Eleven research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $97.96.

Insider Buying and Selling

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the transaction, the director now directly owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 456,234 shares of company stock valued at $42,130,461 over the last ninety days. 0.16% of the stock is owned by company insiders.

Gilead Sciences Trading Up 0.2 %

Shares of Gilead Sciences stock opened at $93.07 on Friday. The company’s fifty day simple moving average is $91.65 and its 200-day simple moving average is $84.68. The company has a market cap of $115.99 billion, a price-to-earnings ratio of 1,034.11, a PEG ratio of 1.31 and a beta of 0.18. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $98.90.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period last year, the business earned $2.29 earnings per share. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were given a $0.77 dividend. The ex-dividend date was Friday, December 13th. This represents a $3.08 annualized dividend and a yield of 3.31%. Gilead Sciences’s dividend payout ratio (DPR) is currently 3,422.22%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.